BIAS
ALNY icon

Beacon Investment Advisory Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Beacon Investment Advisory Services’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.8K Sell
99
-111
-53% -$33.5K ﹤0.01% 492
2026
Q1 		$69.5K Buy
+210
New +$71.5K ﹤0.01% 377
2025
Q4 		– Sell
-585
Closed -$267K – 263
2025
Q3 		$267K Sell
585
-705
-55% -$287K 0.01% 220
2025
Q2 		$421K Sell
1,290
-398
-24% -$110K 0.02% 180
2025
Q1 		$456K Sell
1,688
-2,033
-55% -$522K 0.02% 172
2024
Q4 		$876K Sell
3,721
-680
-15% -$179K 0.04% 139
2024
Q3 		$1.21M Sell
4,401
-235
-5% -$61.2K 0.05% 133
2024
Q2 		$1.13M Sell
4,636
-382
-8% -$60.3K 0.05% 131
2024
Q1 		$750K Sell
5,018
-437
-8% -$72.9K 0.03% 152
2023
Q4 		$1.04M Sell
5,455
-1,660
-23% -$283K 0.05% 141
2023
Q3 		$1.26M Sell
7,115
-3,041
-30% -$580K 0.06% 138
2023
Q2 		$1.93M Sell
10,156
-301
-3% -$59.7K 0.09% 128
2023
Q1 		$2.09M Sell
10,457
-183
-2% -$38.5K 0.1% 123
2022
Q4 		$2.53M Sell
10,640
-39
-0.4% -$8.32K 0.13% 114
2022
Q3 		$2.14M Sell
10,679
-227
-2% -$43.3K 0.12% 116
2022
Q2 		$1.59M Sell
10,906
-86
-0.8% -$12.2K 0.08% 132
2022
Q1 		$1.79M Sell
10,992
-21
-0.2% -$3.2K 0.08% 129
2021
Q4 		$1.87M Buy
11,013
+1,732
+19% +$322K 0.07% 137
2021
Q3 		$1.75M Buy
9,281
+346
+4% +$64.9K 0.07% 142
2021
Q2 		$1.51M Buy
8,935
+602
+7% +$88.2K 0.06% 145
2021
Q1 		$1.18M Buy
8,333
+3,803
+84% +$572K 0.05% 149
2020
Q4 		$589K Buy
+4,530
New +$605K 0.03% 174

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Beacon Investment Advisory Services's ALNY Position: Q2 2026 in Review

Beacon Investment Advisory Services reduced its Alnylam Pharmaceuticals (ALNY) stake by 53% in Q2 2026, selling an estimated $33.5K and leaving 99 shares worth $29.8K. The position accounts for ﹤0.01% of the portfolio, ranked #492.

Beacon Investment Advisory Services first reported a position in ALNY in Q4 2020 and has held it in 22 quarters since. The position peaked at $2.53M in Q4 2022. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Beacon Investment Advisory Services held 99 shares of Alnylam Pharmaceuticals worth $29.8K as of Q2 2026.
  • Beacon Investment Advisory Services sold 111 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $33.5K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Beacon Investment Advisory Services's portfolio in Q2 2026, its #492 holding.
  • Beacon Investment Advisory Services first reported a position in Alnylam Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Beacon Investment Advisory Services's Alnylam Pharmaceuticals position peaked at $2.53M in Q4 2022.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Beacon Investment Advisory Services's 13F filing for Q2 2026, filed 8 Jul 2026.